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Introduction: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to its receptors, TRAIL-receptor
1 (TRAIL-R1) and TRAIL-receptor 2 (TRAIL-R2), leading to apoptosis by activation of caspase-8 and the downstream
executioner caspases, caspase-3 and caspase-7 (caspase-3/7). Triple-negative breast cancer (TNBC) cell lines with a
mesenchymal phenotype are sensitive to TRAIL, whereas other breast cancer cell lines are resistant. The underlying
mechanisms that control TRAIL sensitivity in breast cancer cells are not well understood. Here, we performed small
interfering RNA (siRNA) screens to identify molecular regulators of the TRAIL pathway in breast cancer cells.
Methods: We conducted siRNA screens of the human kinome (691 genes), phosphatome (320 genes), and about 300
additional genes in the mesenchymal TNBC cell line MB231. Forty-eight hours after transfection of siRNA, parallel screens
measuring caspase-8 activity, caspase-3/7 activity, or cell viability were conducted in the absence or presence of TRAIL for
each siRNA, relative to a negative control siRNA (siNeg). A subset of genes was screened in cell lines representing
epithelial TNBC (MB468), HER2-amplified breast cancer (SKBR3), and estrogen receptor-positive breast cancer
(T47D). Selected putative negative regulators of the TRAIL pathway were studied by using small-molecule inhibitors.
Results: The primary screens in MB231 identified 150 genes, including 83 kinases, 4 phosphatases, and 63 nonkinases,
as potential negative regulators of TRAIL. The identified genes are involved in many critical cell processes, including
apoptosis, growth factor-receptor signaling, cell-cycle regulation, transcriptional regulation, and DNA repair. Gene-network
analysis identified four genes (PDPK1, IKBKB, SRC, and BCL2L1) that formed key nodes within the interaction network of
negative regulators. A secondary screen of a subset of the genes identified in additional cell lines representing
different breast cancer subtypes and sensitivities to TRAIL validated and extended these findings. Further, we
confirmed that small-molecule inhibition of SRC or BCL2L1, in combination with TRAIL, sensitizes breast cancer
cells to TRAIL-induced apoptosis, including cell lines resistant to TRAIL-induced cytotoxicity.
Conclusions: These data identify novel molecular regulators of TRAIL-induced apoptosis in breast cancer cells
and suggest strategies for the enhanced application of TRAIL as a therapy for breast cancer.* Correspondence: ncaplen@mail.nih.gov; lipkowis@mail.nih.gov
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Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) may have potential use in cancer therapy because
of its ability to kill selectively cancer cells over normal cells
[1-3]. TRAIL binds to its receptors (TRAIL-R1 (DR4) or
TRAIL-R2 (DR5)) on the cell surface, leading to the
recruitment of the adaptor molecule FADD and
pro-caspase-8 [4]. This forms the death-inducing signaling
complex (DISC). Pro-caspase-8 is cleaved to its active form
at the DISC, which then cleaves and activates the down-
stream executioners caspase-3 and caspase-7 (caspase-3/7),
resulting in apoptosis. Active caspase-8 also can cleave the
BH3 protein BID, resulting in activation of the intrinsic
pathway of apoptosis by activating caspase-9 (reviewed in
[5]). Studies in animals have shown that TRAIL mediates
regression of cancer xenografts without affecting normal
tissues, and human phase I studies have demonstrated
that TRAIL agonists are safe [3,6]. However, the re-
sults published thus far have shown limited clinical ef-
ficacy, suggesting the need to identify predictive
biomarkers that will stratify cancers into those more likely
to respond and/or to identify additional genes or path-
ways that can be targeted in combination with TRAIL
to enhance the efficacy of TRAIL agonists [6-14].
Preclinical studies have found that many cell lines of dif-
ferent cancer types are resistant to TRAIL. Initial studies
of TRAIL-induced apoptosis in breast cancer cell lines
demonstrated that although TRAIL could induce apop-
tosis in the MDA-MB-231 (MB231) breast cancer cell line,
the majority of cell lines tested were very resistant to
TRAIL-induced apoptosis [1,15-17]. These studies estab-
lished that TRAIL induced caspase-mediated apoptosis in
sensitive cell lines and that TRAIL activated caspases
within minutes of addition to the cells [16,18]. Data
from three independent studies, including ours, dem-
onstrated that 10 of 14 triple-negative breast cancer
(TNBC) cell lines were sensitive to TRAIL-induced
apoptosis, whereas only two of eight HER2-amplified
cell lines, and none of seven estrogen receptor (ER)-
positive lines were sensitive to TRAIL-induced apop-
tosis [5,15,19,20]. Among the TNBC subtype, cells with
mesenchymal features are more sensitive to TRAIL
than are cells with epithelial features [20]. However,
the underlying determinants of TRAIL sensitivity in the
breast cancer cell lines have not been clearly established.
In this study, we took advantage of RNAi screening tech-
nology to identify novel molecular regulators of TRAIL-
induced apoptosis in breast cancer cells. By using synthetic
siRNA-mediated RNAi screens of the human kinome,
phosphatome, and about 300 additional genes, we identi-
fied a subset of 150 genes that, when silenced, enhance
TRAIL-induced caspase-3/7 activation in MB231 cells.
These genes can be grouped into cellular networks that
modulate the sensitivity to TRAIL in breast cancer cells.Analysis of the caspase-8 activation and cell viability RNAi
screening data for those genes associated with these cellu-
lar networks corroborated a potential role for many of
these proteins in regulating TRAIL-mediated apoptosis
and cytotoxicity. RNAi screening of a subset of the identi-
fied genes in a panel of breast cancer cell lines representing
different breast cancer subtypes (TNBC, HER2-amplified,
and ER-positive) identified potential targets that may have
broad application in enhancing TRAIL activity in breast
cancer cells. Importantly, pharmacologic inhibition of two
targets identified by RNAi screening, SRC or BCL2L1
(BCL-XL), sensitized cell lines known to be resistant to




The MB231, HCC38, BT549, BT474, MCF7, Hs578T,
and SKBR3 breast cancer cell lines were obtained from
ATCC; BT20 and HCC1937 were obtained from Rein-
hard Ebner (Avalon Pharmaceuticals; Germantown, MD,
USA). All cells were grown in RPMI 1640 medium sup-
plemented with 10% FBS and 1% Pen-Strep (R10). This
research was performed with anonymized breast cancer
cell lines and is exempt from ethics or IRB approval.
Inhibitors and reagents
The GST-TRAIL construct and the isolation of recom-
binant GST-TRAIL fusion protein have been previously
described [16]. The inhibitors PP2 (529573) and PP3
(529574) were obtained from Calbiochem (La Jolla, CA,
USA), ABT-737 (S1002) was obtained from Selleck Che-
micals (Houston, TX, USA), and DEVD-CHO (P410), from
Biomol International (Plymouth Meeting, PA, USA). All in-
hibitors were dissolved in DMSO. Caspase-Glo 8 assay
(G8202) and Caspase-Glo 3/7 assay (G8092), and Caspase-
Glo 9 (G8210) systems were purchased from Promega Cor-
poration (Madison, WI, USA).
Caspase-activation assays, cell-viability assays, RNAi
screening, and small-molecule-compound analysis
Primary RNAi screens were conducted by using siRNAs
corresponding to 1,135 genes arrayed from the Human
Druggable Genome Version 2.0 library (Qiagen Inc.). The
siRNAs target 691 genes annotated as associated with kin-
ase activity, 206 genes associated with phosphatase activ-
ity, and 238 additional genes that include members of the
ABC transporter family and several apoptosis-associated
genes. The majority of the genes within the kinase and
phosphatase sets encode proteins with defined kinase or
phosphatase activity, respectively, although a limited
number act as enzyme co-factors, and a few have been
re-annotated now as pseudogenes or withdrawn. See
Additional file 1: Table S1 for full details of genes targeted.
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ary screening are detailed in Additional file 2: Table S2.
For screening (primary and secondary), four siRNAs
per gene were arrayed in 384-well plates, one siRNA per
well. For each well, 2 pmol siRNA was complexed with
0.06 μl RNAiMax transfection reagent (Invitrogen; Grand
Island, NY, USA) in 20 μl RPMI for 15 minutes at ambient
temperature. Six hundred cells in 20 μl RPMI-1640/20%
FBS were added to each well. Plates were maintained at
room temperature for 15 minutes before incubation at 37°
C/5% CO2. Paired screens were conducted: 48 hours after
siRNA transfection, one screen received vehicle only
(medium), whereas the other received 1,000 ng/ml TRAIL
(in medium) for 1 hour for the study of caspase-3/7 and
caspase-8 activation or 100 ng/ml of TRAIL (in medium)
for 24 hours for the study of cell viability. The activation
of caspase-8 and caspase-3/7 was measured by using Cas-
pase Glo Assay systems following the manufacturer’s in-
structions (Promega Corporation with modification of the
caspase-8 assay to block caspase-3/7-induced activation of
caspase-8 (see Results for further details). Cell viability
was measured by using Cell Titer Glo assay following the
manufacturer’s instructions (G7572; Promega Corpor-
ation). All assay plates were measured with a Victor
luminometer (Perkin Elmer, Waltham, MA, USA). The
kinome and additional sets were screened together,
whereas the phosphatase gene set was screened separ-
ately. As these screens were conducted at different
times, the data for each screen was initially analyzed
independently. To validate each screen, untransfected
cells (cells only) and wells transfected with negative
(AllStars Negative Control siRNA (siNeg); Qiagen, Valencia,
CA, USA) and positive (AllStars Hs Celldeath siRNA
(siCelldeath); Qiagen) control siRNAs were included
on every plate, as were siRNAs corresponding to CASP8
and FLIP (siCASP8, L003466 and siFLIP, L003772; from
Dharmacon, Thermo Fisher Scientific, Waltham, MA).
The data for each experimental siRNA were normalized
by using the average value for siNeg-transfected cells
without TRAIL for each plate. The data for all three
screens are detailed in Additional file 1: Table S1.
For assay development and treatment with the SRC or
BCL-XL inhibitors, cell viability was assessed by using the
Cell Titer 96AQueous One Solution Cell Proliferation
Assay (G3582) from Promega Corporation. All measure-
ments were performed in replicates of six wells in a 96-well
plate, and each experiment was carried out at least 3 times.
Results are presented as the mean ± the standard error of
the mean (SEM) of at least three independent experiments.
Lysate preparation and immunoblotting
Cell lysates were made, and immunoblotting was per-
formed as described earlier [20]. The following antibodies
were used: anti-AKT (#4685), anti-phospho-AKT (T308;#4056), anti-caspase-8 (1C12; #9746), anti-ERK 1/2 (#9102),
anti-phospho-ERK 1/2 (#9101), anti-GAPDH (#2118), anti-
p70S6K (#2708), and anti-phospho-p70S6K (S371; #9205)
from Cell Signaling Technology, anti-FLIP (#104) from
Imgenex (San Diego, CA, USA), anti-SRC (#OP07) from
EMD Millipore (Billerica, MA, USA), anti-phospho-SRC
(#44-660G) from Life Technologies (Grand Island, NY,
USA), and anti-Tubulin (#T9026) from Sigma Aldrich (St.
Louis, MO, USA).
Statistics and bioinformatics analysis
Student's t test (unequal variance) was used to deter-
mine statistical differences between siRNA control groups
(calculated in Excel). A value of P < 0.05 was considered
significant. A Pearson correlation coefficient was used to
compare the relation between screens and was calculated
in Excel. Paired Student's t tests were also performed to
analyze the data for treatment with the SRC or BCL-XL
inhibitors. To compare the effect of the combined treat-
ment to the sum of the effects of the individual treatments,
percentage inhibition was calculated for each condition as
100% viability. The inhibition of the combination was com-
pared with the sum of the inhibition of TRAIL alone plus
inhibitor alone. Knowledge-based gene networks were gen-
erated by using Ingenuity Pathway Analysis (IPA) tools
(Ingenuity Systems; Redwood City, CA, USA).
Results
The development of assays for RNAi screens of TRAIL-induced
apoptosis
To identify regulators of TRAIL-induced apoptosis, we
established conditions compatible with siRNA-based RNAi
screening for three assays that assess different steps in the
TRAIL-induced apoptotic pathway in the MB231 breast
cancer cell line. We chose to use the TRAIL-sensitive
MB231 cell line and a concentration of TRAIL that in-
duced approximately 50% maximum activity in each assay
to enable identification of both positive and negative regu-
lators of the TRAIL pathway. We used two assays that
measured activation of caspases by TRAIL, one for activa-
tion of the initiator caspase-8, and one for the activation of
the downstream effector caspases-3 and -7 (caspases-3/7).
We also used an assay of cell viability (Figure 1A).
Assays were optimized to detect measurable levels of
caspase-8 and caspase-3/7 activity by using substrates
specific for each caspase. To identify an appropriate con-
centration of TRAIL to be used for identification of pro-
teins that modulate early steps in TRAIL-induced apoptosis,
MB231 breast cancer cells were treated with different con-
centrations of TRAIL and, after 1 hour, caspase activity was
measured. A TRAIL concentration-dependent increase in
activity was observed for both caspase-8 and caspase-3/7
(Figure 1B). At 1,000 ng/ml of TRAIL, we detected a sixfold
change in caspase-3/7 activity and a 4.8-fold change in
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Figure 1 The development of siRNA-based RNAi screens for the identification of regulators of TRAIL-induced apoptosis in the MB231 breast
cancer cell line. (A) A diagrammatic representation of the extrinsic TRAIL-induced apoptotic pathway. RNAi screens were developed assaying caspase-8
activation (Screen 1), caspase-3/7 activation (Screen 2), and cell viability (Screen 3) in the absence and presence of TRAIL. Synthetic siRNAs corresponding
to CASP8 and FLIP were used as positive and negative regulator controls of the TRAIL pathway, respectively. The caspase-3/7 DEVD-CHO inhibitor is
shown on the diagram. (B) Caspase-3/7 and caspase-8 activity was measured by using caspase-3/7 and caspase-8-Glo assays. MB231 cells were treated
with increasing concentrations of TRAIL (as indicated) or RPMI medium for 1 hour, after which caspase activity was measured. Fold-increase in caspase
activity is plotted relative to the untreated cells. Data are shown as the mean and standard error of three experiments. (C) Caspase-3/7 and caspase-8
activity were measured after pretreatment with or without 0.03 μM DEVD-CHO for 1 hour and then treatment with 1,000 ng/ml TRAIL for 1 hour.
Inhibition with DEVD-CHO blocked caspase-3/7 activity significantly compared with caspase-8 activity. Data are shown as the mean and
standard error of three experiments. (D) Viability of MB231 cells was measured by an MTS assay 48 hours after the transfection of the negative-control
siRNA (siNeg) or siRNAs corresponding to CASP8 and FLIP, respectively, either in the absence or presence of 1,000 ng/ml TRAIL for 17 hours. Data are
shown as the mean and standard error of three experiments. (E) Western-blot analysis of cell lysates for CASP8 and FLIP expression, 48 hours after the
transfection of the negative control siRNA (siNeg) or siRNAs corresponding to CASP8 and FLIP, respectively.
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of TRAIL used to induce robust caspase activation
within the 1-hour caspase assays is a much higher con-
centration than that needed to induce loss of viability
when cells were exposed to TRAIL for >17 hours to
assess cytotoxicity (discussed later).Caspase-8 is the first caspase to be activated on TRAIL
binding to its receptors. Also, caspase-8 can be activated
in a retrograde fashion by active caspase-3/7 (Figure 1A)
[21,22]. To measure the caspase-8 activity triggered by the
TRAIL receptors and not that produced from active
caspase-3/7, we treated cells with a caspase-3/7 inhibitor,
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In the presence of 0.03 μM DEVD-CHO, TRAIL-induced
caspase-3/7 activity was inhibited to baseline levels in
comparison with 5.5-fold activation over the untreated
controls. By contrast, only a slight loss was found in
TRAIL-induced caspase-8 activation in the presence of
DEVD-CHO compared with TRAIL-induced activation
of caspase-8 in the absence of DEVD-CHO (threefold
versus 3.8-fold). Therefore, to ensure direct measure-
ment of TRAIL-receptor-mediated caspase-8 activation,
we used 0.03 μM DEVD-CHO in our screening assay of
caspase-8 activation.
To develop the screening assays further, we used control
siRNAs corresponding to a positive effector of TRAIL-
induced apoptosis, caspase-8 (CASP8), and a known nega-
tive regulator of TRAIL-induced apoptosis, the FLICE-like
inhibitory protein (FLIP, a.k.a. CFLAR; [5]) (Figure 1A).
Silencing of CASP8 should lead to the suppression of
apoptosis that can be assayed as an inhibition of caspase-8
and caspase-3/7 activation and a reduction in TRAIL-
induced cytotoxicity. In contrast, silencing of FLIP should
enhance the activation of caspase-8 and caspase-3/7 and
further sensitize cells to TRAIL-induced cytotoxicity. We
confirmed the effects of silencing CASP8 and FLIP by
transfecting MB231 cells with specific siRNAs for these
genes and, 48 hours later, treating with 100 ng/ml of
TRAIL. Control cells were transfected with a control siRNA
(siNeg). Seventeen hours after the addition of TRAIL, cell
viability was measured by MTS assay, and the values were
plotted relative to untreated siNeg transfected cells
(Figure 1D). In the siNeg-transfected control cells, treat-
ment with TRAIL resulted in 49.0% ± 9.5% cell death.
Caspase-8 is a known positive regulator of the TRAIL-
induced apoptotic pathway, and its silencing resulted in
decreased caspase activation similar to that of untreated
cells. Upon silencing of CASP8 and treatment with TRAIL,
viability was 92.7% ± 10.45% and not statistically different
from untreated CASP8-silenced cells (104.97% ± 12.73%).
FLIP structurally resembles caspase-8, but lacks the pro-
teolytic activity, and is a competitive inhibitor of the
TRAIL pathway. The silencing of FLIP enhanced the sensi-
tivity of MB231 cells to TRAIL, as measured by increased
loss of cell viability (68.0% ± 2.0%) compared with siNeg-
transfected cells. Thus, siRNAs corresponding to CASP8
(siCASP8) and FLIP (siFLIP) were used as controls for
positive and negative regulators of the TRAIL pathway, re-
spectively, in all of the RNAi screens.
RNAi screens of the TRAIL-induced apoptotic pathway in
the breast cancer cell line MB231
RNAi screens designed to interrogate different aspects
of the TRAIL-induced apoptotic pathway by measuring
caspase-8 activation, caspase-3/7 activation, and cell via-
bility were performed as described in the Materials andMethods. The kinome and additional gene sets were
screened together by using all three-assay end points.
The phosphatase gene set was screened separately by
using just the caspase-3/7 activation and cell-viability as-
says. The kinome and additional gene sets were screened
and analyzed together, whereas the phosphatase gene set
was screened and analyzed separately. To validate each
screen, wells of untransfected cells (cells only) and wells
transfected with negative (siNeg) and positive (siCelldeath)
control siRNAs were included on every plate, as were wells
of siRNAs corresponding to CASP8 and FLIP. A summary
of the controls for the kinome/additional gene-set screen is
shown in Figure 2A, and for the phosphatase gene-set
screen, in Additional file 3, Figure S1A. The Z-factor values
for each assay are shown in Additional file 4: Table S3.
In the absence of siRNA or in the siNeg-treated cells,
TRAIL induced a twofold to 2.5-fold increase in caspase-8
activity and sixfold to sevenfold increase in caspase-3/7
activity (Figure 2Ai and 2Aii, respectively). Silencing of
CASP8 resulted in a significant reduction of TRAIL-
induced caspase-8 and −3/7 activities, similar to the level
of untreated cells (Figure 2Ai and 2Aii, respectively).
Conversely, silencing of FLIP resulted in a statistically
significant increase in caspase-8 or caspase-3/7 activity
(Figure 2Ai and 2Aii, respectively). TRAIL induced an
approximately 50% reduction in cell viability in untreated
or siNeg-transfected cells (Figure 2Aiii). Silencing CASP8
completely blocked the TRAIL-induced loss of viability,
whereas silencing FLIP resulted in a significantly greater
TRAIL-induced loss of viability (Figure 2Aiii). Similar re-
sults for caspase-3/7 activation and viability were seen in
the control samples for the siRNA screen of the phosphat-
ase gene set (Additional file 3: Figure S1A). The data for
each experimental siRNA were normalized by using the
average value for siNeg-transfected cells without TRAIL
for each plate. The data for all three screens are detailed
in Additional file 1: Table S1.
We first evaluated the correlation between the results
for each siRNA in the three screens, a total of more than
4,000 data points (Figure 2B and C). In the absence of
TRAIL, few siRNAs affected caspase-8 or caspase-3/7
activation or the viability of MB231 cells (Figure 2B). Al-
though, for example, we did observe that three of four
siRNAs corresponding to PLK1 induced activation of
caspase-8, caspase-3/7, and a decrease in viability in the
absence of TRAIL (Additional file 3: Figure S1B), which is
consistent with previous studies [23]. In contrast, in the
presence of TRAIL, a substantial number of siRNAs in-
creased activation of caspase-8 and caspase-3/7, and de-
creased the viability of MB231 cells in response to TRAIL
(Figure 2C). Importantly, in the presence of TRAIL, a posi-
tive Pearson correlation of 0.47 was observed when levels
of caspase-8 and caspase-3/7 were compared, whereas
negative correlations were observed when caspase-8
Figure 2 (See legend on next page.)
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Figure 2 Caspase-8, caspase-3/7, and cell-viability RNAi screens of TRAIL-induced apoptosis in MB231 cells. (A) Controls included in the
RNAi screens for (i) caspase-8 activation, (ii) caspase-3/7 activation, and (iii) cell viability in the absence (white bars) or presence (black bars) of
TRAIL. For assessment of caspase-8 and caspase-3/7 activation, cells were siRNA-transfected and, 48 hours later, were treated with 1,000 ng/ml
TRAIL for 1 hour. For assessment of cell viability, cells were siRNA-transfected, and 48 hours later were treated with 100 ng/ml TRAIL for 17 hours.
Data are normalized to the mean value of negative control siRNA (siNeg)-transfected cells in the absence of TRAIL and are shown as the mean
and standard deviation for each group by using the following number of wells: cells only, between 318 and 384 wells; and siRNA-transfected
between 48 and 96 wells. Comparison of TRAIL-treated with siNeg-transfected untreated cells demonstrated a significant increase in
caspase-8 and caspase-3/7 activation and a decrease in viability. siCASP8 reduced caspase-8 (P = 3 × 10-21) and caspase-3/7 (P = 2.5 × 10-22)
activation and increased viability (P = 1.0 × 10-48) compared with siNeg-transfected cells. siFLIP significantly increased caspase-8 (P = 7.0 × 10-5)
and caspase-3/7 (P = 2.3 × 10-58) activation and decreased viability (1.0 × 10-67) compared with siNeg-transfected cells. ***P < 0.001, by using a
two-tailed Student's t test. (B) Scatterplots comparing results for each siRNA (total of 4,540) in each screen in the absence of TRAIL: (i) activation of
caspase-3/7 versus caspase-8, (ii) activation of caspase-8 versus cell viability, and (iii) activation of caspase-3/7 versus cell viability. (C) Scatterplots
comparing results for each siRNA (total of 4,540) in each screen in the presence of TRAIL: (i) activation of caspase-3/7 versus caspase-8, (ii) activation of
caspase-8 versus cell viability, and (iii) activation of caspase-3/7 versus cell viability. The trend line for each data comparison is shown as the Pearson
correlation (r).
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cell viability (caspase-8 versus cell viability: r = −0.23;
and caspase-3/7 versus cell viability: r = −0.55). These
data demonstrated that the effects on caspase activa-
tion and cell viability were generally consistent for
each of the individual siRNAs.
The identification of putative regulators of the TRAIL pathway
Of the three RNAi screening end points, overall, the
siRNA screens of TRAIL conducted by using caspase-3/
7 as an end point showed the greatest range of fold-
change in activation relative to controls (up to >30-fold).
Thus we chose to focus on the results of the caspase-3/7
screen to initially identify regulators of TRAIL and use
the caspase-8 and cell-viability screening data to corrob-
orate our findings. We defined putative negative regula-
tors of TRAIL as those genes for which at least three of
the four siRNAs tested caused an increase in TRAIL-
induced caspase-3/7 activation two standard deviations
or more from the TRAIL-induced caspase-3/7 activation,
seen with the control siNeg siRNA. This corresponded to
a >10.28-fold change for the kinase and additional gene
set screens and a >7.96-fold change for the phosphatase
gene set. These fold changes were comparable with that
seen after silencing of the negative regulator FLIP (10.58-
fold change for the kinase and additional gene-set screens
and 7.54-fold for the phosphatase gene set). These criteria
identified 83 kinases or kinase-related genes (Figure 3A),
four phosphatases (Figure 3B), and 63 genes from the add-
itional gene set (Figure 3C), whose silencing augmented
TRAIL-induced caspase-3/7 activity. The screen identified
several known negative regulators of apoptosis as negative
regulators of TRAIL-induced caspase-3/7 activation, in-
cluding BCL2L1 (BCL-XL), BCL2L2 (BCL-w), BIRC2
(c-IAP1), and BIRC3 (c-IAP2) [24,25].
Also we assessed whether any genes act as positive
regulators of TRAIL activity. We defined positive regula-
tors of TRAIL-induced caspase activation as those genes
in which at least three of four siRNAs resulted in TRAIL-induced caspase-3/7 activation that was two or more
standard deviations less than that seen in cells treated with
the siNeg control (a <4.06-fold change for the kinase and
additional gene-set screens and a <2.77-fold change for
the phosphatase gene set). Interestingly, with these cri-
teria, no positive regulators of TRAIL-induced caspase-3/
7 activation were identified. Silencing of CASP8 clearly
inhibited TRAIL-induced activation of caspase-3/7 by
more than 2 standard deviations, indicating that the
screen was capable of identifying such genes (Figure 2Aii).
Relaxing the criteria to siRNAs that resulted in more
than a 1 standard deviation reduction in TRAIL-induced
caspase-3/7activation compared with the siNeg-control,
identified eight genes as putative positive regulators of
TRAIL-induced caspase-3/7 activation (NEK6, ETNK1,
NME5, PXK, CALM2, RPS6KB2, GK5/MGC40579, and
AKR1B1; Additional file 3: Figure S1C).
Gene-network analysis and experimental corroboration of
negative regulators of TRAIL
We focused our subsequent analysis on putative negative
regulators of TRAIL-induced caspase-3/7 activation ra-
ther than on positive regulators because of the number
of genes identified and because they may be potential
targets that, when inhibited, will enhance TRAIL-induced
apoptosis. Given the relatively large number of putative
negative regulators of TRAIL-induced apoptosis, we sub-
jected the 150 genes to network gene analysis to aid in
identification of common regulatory networks in which
these genes function. Of the 147 genes with curated inter-
action data, the largest network identified connected 79
genes (see Additional file 5: Figure S2). Of these 79 genes,
42 were connected principally via four genes with seven
or more interactions (Figure 4A). The genes situated at
these nodes are BCL2L1 (BCL-XL), IKBKB, PDPK1, and
SRC (indicated by the blue circles in Figure 4A).
To investigate further the TRAIL-associated loss-of func-
tion (LOF) phenotype of the 79 genes that formed this































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 The identification of putative negative regulators of TRAIL-induced apoptosis by using siRNA-enhanced activation of caspase-3/7
in the presence of TRAIL. Genes for which three or four siRNAs mediated a fold change in the activation of caspase-3/7 in the presence of TRAIL
of two or more standard deviations more than that observed in control siRNA (siNeg)-transfected cells plus TRAIL were considered putative
negative regulators of TRAIL-induced apoptosis. The dashed line in each panel indicates the 2- standard deviation fold change, and a vertical line
joins those siRNAs that induced at least this level of change for each gene. Data for the control siRNAs, siNeg, siCASP8, and siFLIP are included for
reference and represent the same data for the siRNAs, indicated as shown in Figure 2Aii and Additional file 3: Figure S1Ai. (A) Genes identified
from the kinase gene set. (B) Genes identified from the phosphatase gene set, and (C) genes identified from the additional gene set. Genes are ranked
in descending order based on the median value for each set of four siRNAs per gene.
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http://breast-cancer-research.com/content/16/2/R41these genes on caspase-8 activation and cell viability in the
presence of TRAIL. Three or more siRNAs against 26 of
the 79 genes that enhanced TRAIL-induced activation of
caspase-3/7 also enhanced TRAIL cytotoxicity by greaterthan 2 standard deviations from the mean viability seen in
siNeg-transfected cells plus TRAIL. As indicated by the
red rectangles in Figure 4A, 14 of these 26 genes map to
the direct interaction network. The silencing of BCL2L1
BCL2L1
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Figure 4 Network analysis of putative negative regulators of TRAIL-induced apoptosis. (A) A gene-interaction network generated by Ingenuity
Pathway Analysis of the 150 genes for which three or more siRNAs induced increased TRAIL-induced activation of caspase-3/7 levels. The blue
circles indicate those genes with seven or more interactions, and the red rectangles, genes for which three or more siRNAs caused both an
increase in TRAIL-induced activation of caspase-3/7 levels and decreased viability in response to TRAIL. Legend shows the symbols indicated
by the Ingenuity Pathway Analysis software. (B) Assays of (i) caspase-8, (ii) caspase-3/7 activation, and (iii) cell viability in the absence (empty
bars) and presence (black bars) of TRAIL for four siRNAs (A-D) corresponding to the genes shown. Average data (±1 standard deviation) for
negative control siRNA (siNeg)-transfected cells is shown in each graph. The grey dashed line indicates the relevant 1 standard deviation
value for each assay, and the red dots indicate those siRNAs inducing fold-changes greater than 1 standard deviation.
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multiple siRNAs increased TRAIL-induced caspase-3/7 ac-
tivation and cytotoxicity (Figure 4B and Additional file 6:
Figure S3). In addition, the RNAi induced LOF of several
genes linked to SRC enhanced TRAIL-induced cytotoxicity
including PDPK1, CNKSR1, PIP5K1C, FGFR4, BCR,
RIOK3, and MKNK1 (Figure 4B and Additional file 6:
Figure S3). All three of the siRNAs corresponding to SRC
that activated caspase-3/7 in the presence of TRAIL en-
hanced cytotoxicity, but only by using a relaxed criterion
of greater than 1 standard deviation from the mean viabil-
ity seen in siNeg-transfected cells plus TRAIL (Additional
file 6: Figure S3). Multiple siRNAs corresponding to
PDPK1 and several genes linked to PDPK1 (Figure 4B)
also increased TRAIL-induced caspase-3/7 activation
and cytotoxicity. These included PRKC1, the known apop-
tosis inhibitor BIRC2 (a.k.a., cIAP-1), PLK3, PKN1, and
ACTN4 (Additional file 6: Figure S3). Silencing by two of
four siRNAs of many of the remaining genes mapping to
the direct interaction network induced a decrease in cell
viability greater than 2 standard deviations from that seen
in siNeg-transfected cells plus TRAIL, with at least one
further siRNA inducing a decrease in viability at least 1
standard deviation from that seen in siNeg-transfected
cells plus TRAIL. This included silencing of IKBKB
(Additional file 6: Figure S3), BLK, ERBB2, FGFR2,
NAGK, and ZC3HC1 (PARP12).
The results for the activation of caspase-8 were more
variable. Only one gene BCL2L1 (BCL-XL) showed an
increase in caspase-8 levels more than 1 standard devi-
ation from that seen in siNeg-transfected cells for three
or more siRNAs (Figure 4Bi). In several other cases, two
of four siRNAs corresponding to a specific gene medi-
ated an increase in caspase-8 levels more than 1 stand-
ard deviation from that seen in siNeg, including CNKSR1,
BCR, and PIP5KIC, which all linked to SRC (Figure 4Bi
and Additional file 6: Figure S3), ATP5A1 that links to
BCL2L1 (Additional file 6: Figure S3), and PRKC1, which
is linked to PDPK1 (Additional file 6: Figure S3). Two
genes for which three siRNAs activated caspase-3/7
and −8 but did not map to the network based on direct
interactions, BCL2L2 and APEX1. Interestingly, all four
siRNAs corresponding to BCL2L2 (BCL-w) enhancedTRAIL-induced caspase-3/7 activation, and three of
these siRNAs also enhanced TRAIL-induced caspase-8
activation, but no effect on cell viability was observed
(Additional file 6: Figure S3). Three siRNAs corre-
sponding to the APEX nuclease (multifunctional DNA
repair enzyme) 1 gene, APEX1, enhanced TRAIL-activated
caspase-3/7 and caspase-8 and decreased cell viability, but
the individual siRNAs that generated these phenotypic
changes were inconsistent (Additional file 6: Figure S3).
Secondary RNAi screen validation in additional breast
cancer cell lines
To validate a subset of the genes identified by the primary
siRNA screen in MB231 as putative negative regulators of
TRAIL activity, we selected 16 genes for secondary screen-
ing in four breast cancer cell lines and assayed caspase-3/7
activation. Fifteen of the genes chosen (annotated by red
boxes in Figure 4) were those that, when silenced, induced
both an increase in activation of caspase-3/7 and a decrease
in viability in response to TRAIL (Figures 4 and Additional
file 6: Figure S3). We also included IKBKB, as this formed a
node in the interaction map with seven or more interactions,
and when silenced, three of four siRNAs induced an increase
in TRAIL-induced activation of caspase-3/7, and two of four
siRNAs decreased viability in response to TRAIL (Figures 4
and Additional file 6: Figure S3).
For the secondary screen, we used MB231 and three
additional breast cancer cell lines (MB468, SKBR3, and
T47D) representing different subsets of breast cancer
with different sensitivities to TRAIL. The MB231 cell
line is a basal B/TNBC cell line, MB468 is a basal A/
TNBC cell line, SKBR3 is a HER2 amplified cell line,
and T47D is an ER-positive cell line [20,26]. Upon treat-
ment with TRAIL, a robust activation of caspase-3/7
occurs in the MB231 cell line, an intermediate activation
of caspase-3/7 in the MB468 cell line, and little or no
caspase-3/7 activation in the SKBR3 and T47D cell lines
(see Additional file 7: Figure S4). The siRNAs used for
the secondary screen are listed in Additional file 2: Table
S2. Some of the siRNAs used in the primary screen were
no longer available, and substitutes were obtained.
The results for the secondary screen are detailed in
Figure 5 and Additional file 8: Table S4 and summarized
Figure 5 (See legend on next page.)
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Figure 5 A secondary screen of putative negative regulators of TRAIL-induced apoptosis. Four siRNAs corresponding to 16 genes were
selected for additional analysis of TRAIL-induced caspase-3/7 activation in (A) MB231, (B) MB468, (C) T47D, and (D) SKBR3. Cells were siRNA
transfected, as for the primary screen, and 48 hours later were treated with 1,000 ng/ml TRAIL for 1 hour before assessment of caspase-3/7
activation. The dashed line in each panel indicates the 2-standard deviation fold-increase in TRAIL-induced caspase-3/7 activation compared
with TRAIL-treated cells transfected with negative control siRNA (siNeg). The vertical line joins the siRNAs for each gene. Genes are ranked in
descending order based on the median value for each set of four siRNAs per gene in the MB231 cell line. Data for the control siRNAs, siNeg,
siCASP8, and siFLIP are included for reference.
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silencing of 13 of the 16 genes again showed a 2-standard
deviation increase in TRAIL-induced caspase-3/7 activity
by three or more of the siRNAs to each target (Figure 4A
and Table 1 and Additional file 8: Table S4). We used two
criteria to rank the degree of validation of a gene as a
negative regulator of TRAIL-induced apoptosis based on
three or more siRNAs corresponding to each gene enhan-
cing TRAIL-induced caspase-3/7 activation by either (a)
greater than 2 standard deviations (indicated in Table 1 as
a +; high stringency) or (b) greater than 1 standard de-
viation (indicated in Table 1 as a (+); low stringency)
from that observed in siNeg-transfected cells treated
with TRAIL.
In MB231 cells, 13 of the 16 genes were validated at
high stringency (based on criterion 1). LOF of two genes,
MNNK1 and HIPK2, only replicated when a more-relaxed










ACTN4 + + + +
BCL2L1 + + + (+)
BIRC2 + + (+) +
ATP5A + + + -
BCR + + + -
FGFR4 + + (+) -
PDPK1 + + (+) -
PIP5K1C + + (+) -
RIOK3 + + (+) -
SRC + + (+) -
CNKSR1 + + - -
HIPK2 (+) + - -
MKNK1 (+) + - -
PLK3 + + - -
PRKC1 + + - -
IKBKB - + - -
+ indicates that three or more siRNAs for a target enhanced TRAIL-induced
caspase-3/7 activity by >2 standard deviations (criterion 1).
(+) indicates three or more siRNAs for a target enhanced TRAIL-induced
caspase-3/7 activity by >1 standard deviation (criterion 2).Additional file 8: Table S4). Only LOF of IKBKB failed to
replicate based on the lower stringency although two of
the four siRNAs increased TRAIL-induced caspase-3/7
activation by more than 1 standard deviation. Overall,
these results in MB231 confirmed the reliability of the pri-
mary screen results. Interestingly, LOF of all 16 genes en-
hanced TRAIL-induced caspase-3/7 activation in the
TNBC/basal A cell line MB468 by using the high-
stringency criterion of three or more siRNAs enhancing
TRAIL-induced caspase-3/7 activation by more than 2
standard deviations. (Figure 5B, Table 1, and Additional
file 8: Table S4).
The ER-positive T47D cell line and the HER2-amplified
cell line SKBR3 are resistant to TRAIL-induced cytotox-
icity (Additional file 7: Figure S4). Any alteration in the
sensitivity of these cells to TRAIL is likely to represent an
important regulator of TRAIL and a potential target for
enhancing its activity in breast cancer more broadly. In
T47D cells, the LOF of four genes met the high-stringency
criterion 1 (BCL2L1, BCR, ATP5A1, and ACTN4), and
six additional genes met the lower-stringency criterion
2 (BIRC2, PDPK1, PIP5K1C, FGFR4, SRC, and RIOK3)
(Figure 5C, Table 1, and Additional file 8: Table S4). In
SKBR3, the LOF of only two genes met the high-stringency
criterion (BIRC2 and ACTN4), and the LOF of one add-
itional gene (BCL2L1) met the lower-stringency criterion 2
(Figure 5D, Table 1, and Additional file 8: Table S4). Overall,
this suggests that BCL2L1, BIRC2, and ACTN4 are poten-
tially major regulators of TRAIL-induced caspase-3/7 in
breast cancer and that their LOF has the potential to over-
come resistance to TRAIL-induced cytotoxicity. Other
genes, including ATP5A, BCR, FGFR4, PDPK1, PIP5K1C,
RIOK3, and SRC, also act to regulate TRAIL-induced
apoptosis, but their potential to overcome resistance to
TRAIL-induced cytotoxicity when inhibited may be more
context specific (that is, in a more-restricted subset of
breast cancer cells).
The inhibition of SRC or BCL-XL enhances TRAIL sensitivity
of TRAIL-resistant breast cancer cell lines
To translate the results of the RNAi screens by using a
pharmacologic approach, we chose next to focus on SRC
and BCL2L1 (BCL-XL), for which small-molecule inhibi-
tors are readily available. Based on our siRNA studies, the
LOF of SRC may potentially represent a context-specific
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may modulate TRAIL activity in a broader range of breast
cancer cell types.
In our screen of additional breast cancer cell lines, the
LOF of SRC enhanced TRAIL-induced caspase-3/7 acti-
vation by 2 or more standard deviations in the two
TNBC cell lines MB231 and MB468, and by 1 standard
deviation in the ER-positive cell line T47D (Figure 5,
Table 1, and Additional file 8: Table S4). Inhibition of
SRC in MB231 cells by the SRC-kinase family small-
molecule inhibitor, PP2, resulted in decreased autophos-
phorylation of SRC compared with its nonfunctional
structural analogue, PP3 (Figure 6A) [27]. Prior work
demonstrated that inhibition of SRC led to decreasedIB: pSRC
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Figure 6 Inhibition of SRC sensitizes breast cancer cells to TRAIL. (A)
concentrations of SRC inhibitor PP2 or its inactive analogue PP3 for 1 hour,
of MB231 cell lysates treated with 10 μM PP2, PP3, or DMSO for 4 hours and
pretreatment with PP2 or PP3 for 4 hours followed by the addition of D
Data are the mean ± SEM for three experiments. The comparison betwe
paired, two-tailed Student's t test. (D) Cell-viability assay of MB231 cells t
concentrations of TRAIL treatment for 17 hours. (E) Cell viability of differe
for 1 hour followed by treatment with 125 ng/ml TRAIL for 17 hours, as
three experiments for each cell line, and the data were compared by usin
treatment with TRAIL alone; **P < 0.05 comparing the combination treatm
treatment with the sum of the inhibition by TRAIL alone plus the inhibitoactivation of the PI3 kinase/AKT pathway, and this, in
turn, resulted in increased TRAIL sensitivity [28,29]. To
test this, we examined the effects of PP2 on downstream
signaling pathways and demonstrated that treatment
with PP2 results in a decrease in activated AKT and acti-
vated p70 S6 kinase, as measured by phosphorylation of
these proteins (Figure 6B). By contrast, no effect was
seen in phosphorylation of ERK (Figure 6B).
Silencing of SRC by RNAi followed by TRAIL treat-
ment enhanced caspase-3/7 activation by more than
10-fold over siNeg-treated cells (Figure 3A and Additional
file 1: Table S1). To test whether PP2 has similar ef-
fects, we treated MB231 cells with PP2 or PP3 for


















Western blot analysis of MB231 cell lysates treated with different
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probed for the indicated proteins. (C) Caspase-3/7 activation by
MSO (white bars) or 1,000 ng/ml of TRAIL (black bars) for 1 hour.
en PP2-treated and DMSO-treated cells was performed by using a
reated with 10 μM PP2 or PP3 or DMSO for 1 hour followed by different
nt breast cancer cells after pretreatment with or without 10 μM PP2
measured by MTS assay. Data are shown as the mean ± SEM for
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ent with PP2 alone; and ***P < 0.05 comparing the combination
r alone.
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TRAIL exhibited a sixfold increase in caspase-3/7 ac-
tivity over untreated cells. Inhibition of SRC by PP2
followed by TRAIL treatment resulted in a 40% in-
crease in the caspase-3/7 activity over control cells.
Cells treated with PP3 and TRAIL showed no signifi-
cant increase in caspase-3/7 activation compared with
control cells.
The effect of inhibiting SRC on TRAIL-induced loss of
viability was tested in MB231 cells preincubated with ei-
ther PP2 or PP3 before the addition of TRAIL (Figure 6D).
The IC50 of TRAIL in these cells was about 125 ng/ml;
the SRC inhibitor, PP2, by itself did not affect cell viability
at 10 μM (92.9% ± 2.3%), but the sensitivity of the cell line
to TRAIL was significantly enhanced in the presence of
PP2 with an IC50 for TRAIL of approximately 32 ng/ml in
the presence of PP2 (P < 0.05). The inactive compound,
PP3, had little or no effect alone or in combination with
TRAIL.
Previously we showed that TNBC cells are more sensi-
tive to TRAIL than are other subtypes of breast cancer
[20]. We next investigated whether SRC inhibition would
sensitize TRAIL-resistant cells to TRAIL by testing the
combination of TRAIL ± PP2 on a panel of breast cancer
cell lines representing ER-positive (T47D or MCF7),
HER2 amplified (SKBR3, BT474, HCC1954, MB453),
TNBC/basal A (HCC1937, BT20, MB468), and TNBC/
basal B (MB231, MB157, Hs578t) subtypes (Figure 6E).
The combination of TRAIL and PP2 was more effect-
ive than TRAIL alone in all cell lines tested (*P ≤ 0.05)
and was more effective than PP2 alone in all cell lines
except the HER2-amplified cell line BT474 (**P ≤ 0.05).
When the inhibition of viability by the combined treat-
ment was compared with the sum of the inhibition seen
with TRAIL alone and PP2 alone, a significant difference
was seen in the TNBC/basal B cell lines MB231 and
Hs578t, and the TNBC/basal B cell line HCC1937 (***P ≤
0.05). Although the combination appeared more active
than the sum of the two agents alone in the TNBC/basal
B cell line MB157, these data did not reach statistical sig-
nificance, in part because of the high sensitivity to TRAIL
alone in this cell line. In the other cell lines, although the
combination was more toxic than either treatment alone,
the effects were relatively modest and not greater than the
sum of the individual treatments (Figure 6E).
Our primary screen identified BCL2L1 (BCL-XL) and
BCL2L2 (BCL-w), known negative regulators of the mito-
chondrial (intrinsic) apoptosis pathway, as putative nega-
tive regulators of TRAIL-induced apoptosis in MB231 cells
(Figure 3). Further, BCL2L1 was identified as a node in the
gene-interaction network generated by using our RNAi
screening data (Figure 4). Silencing of BCL2L1 enhanced
TRAIL-induced caspase activation in three of the four cell
lines tested at high stringency (2-standard deviation cutoff)and in all four lines if a lower stringency was used (Figure 5,
Table 1, and Additional file 8: Table S4).
Expression of BCL2L1 (BCL-XL) protein was measured
in the four cell lines assayed in the secondary screen. BCL-
XL was expressed in the four cell lines tested, but it was
expressed at higher levels in the TRAIL-resistant T47D and
SKBR3 cell lines (Additional file 9: Figure S5A). We con-
firmed the enhancement of TRAIL-induced caspase-3/7 ac-
tivity by using five different BCL2L1 siRNAs in the four cell
lines used for in the secondary screen (siRNAs are listed in
Additional file 2: Table S2). All five siRNAs enhanced
TRAIL-induced caspase-3/7 activation by more than 2
standard deviations in the TNBC cell lines MB231 and
MB468 and four of the five enhanced TRAIL-induced
caspase-3/7 activation by more than 2 standard devia-
tions in the ER-positive cell line T47D and in the HER2-
amplified cell line SKBR3 (Figure 7A). These RNAi screens
were performed in 384-well plates. To confirm that the en-
hancement of TRAIL activity correlated with the knock-
down of BCL-XL protein, we tested two of the siRNAs
(siBCL2L1.3 and siBCL2L1.5) in a larger-scale experiment
on MB231 cells. In the previous plate experiments, knock-
down of BCL-XL with siBCL2L1.3 consistently enhanced
TRAIL-induced caspase-3/7 activity more than knockdown
with siBCL2L1.5 (Figure 7A). In the larger-scale experi-
ment, knockdown of BCL-XL by both siRNAs enhanced
TRAIL-induced caspase-3/7 activity, and again, knock-
down of BCL-XL with siBCL2L1.3 was more effective than
knockdown with siBCL2L1.5 in enhancing TRAIL-induced
caspase-3/7 activity across a wide range of TRAIL concen-
trations (see Additional file 9: Figure S5B).
Concordant with the effects on TRAIL-induced caspase-
3/7 activation, siBCL2L1.3 resulted in a greater knockdown
of the BCL-XL protein than siBCL2L1.5 (Additional file 9:
Figure S5B). Thus the degree of BCL-XL protein knock-
down correlated with the effect on TRAIL-mediated
caspase-3/7 activity (Additional file 9: Figure S5B). To-
gether, these data suggest that loss or inhibition of
BCL2L1 may be useful in combination with TRAIL in
a broad spectrum of breast cancer subtypes.
ABT-737 is an inhibitor of BCL-XL (BCL2L1), BCL-w
(BCL2L2), and BCL-2 that has been shown to enhance
cell death, including in MCF7 breast cancer cells and
myeloma cells by binding and inhibiting the activity of
antiapoptotic BCL2 family members [30,31]. Treatment
of MB231 cells with ABT-737 resulted in increased TRAIL-
induced activation of caspase-8, caspase-9, and caspase-3/7
(Figure 7B, compare striped bars with white bars). Unlike
treatment of the cells with siRNA targeting BCL-XL, treat-
ment of the MB231 cells with ABT-737 had no effect on the
levels of BCL-XL protein (see Additional file 9: Figure S5C).
Little or no increase was found in caspase-8, −9, or −3 acti-
vation when ABT-737 was added to cells in the absence of































































































Figure 7 Inhibition of BCL2L1 (BCL-XL) sensitizes breast cancer cells to TRAIL. (A) MB231, MB468, T47D, and SKBR3 cells were incubated
with five different targeting siRNAs for 48 hours, and caspase-3/7 activity was assayed 1 hour after addition of 1,000 ng/ml TRAIL. siNeg, siFLIP,
and siCasp8 are included in each screen as controls. The grey dashed line represents 1-standard deviation increase in TRAIL-induced caspase-3/7
activation compared with TRAIL-treated cells transfected with the siNeg control. The red dots indicate those siRNAs that induced a fold-change
greater than 1 standard deviation. (B) MB231 cells were incubated with TRAIL (1,000 ng/ml), the BCL2 family inhibitor ABT-737 (5 μM), or both in
the presence or absence of DEVD-CHO (30 nM). Activation of caspase-8, caspase-9, and caspase-3/7 as measured by Caspase-Glo assays 1 hour
after TRAIL addition. Data show the mean activity ± SD for one representative experiment. (C) MTS assay to measure cell viability of different
breast cancer cells after pretreatment with or without 5 μM ABT-737 for 1 hour followed by treatment with 8 ng/ml (MB231, Hs578t) or 63 ng/ml
(MB157, BT20, MB468, HCC1937, ZR75, T47D), 250 ng/ml (MB453, HCC1954), or 500 ng/ml (SKBR3) of TRAIL for 17 hours. Data shown are the
mean ± SEM for three experiments for each cell line, and the data were compared by using a two-tailed Student's t test. *P < 0.05, comparing the
combination treatment with TRAIL alone; **P < 0.05 comparing the combination treatment with ABT-737 alone; and ***P < 0.05 comparing the
combination treatment with the sum of the inhibition by TRAIL alone plus the inhibitor alone.
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ily members by ABT-737, the increased TRAIL-induced ac-
tivation of caspase-8 by ABT-737 was unexpected because
ABT-737 works downstream of the initiator caspase-8.
However, prior work demonstrated that caspase-8 can be
activated by caspase-3 in a retrograde fashion, thus making
it both an initiator and executioner caspase [21,22,32-35].
To test this, we measured the activation of caspase-8, −9,
and −3/7 in the presence of the caspase-3/7 inhibitor
DEVD-CHO. A low submaximal concentration of DEVD-
CHO was used (30 nM), as this concentration was found
to inhibit significantly TRAIL-induced caspase-3 activity
but not to inhibit TRAIL-induced caspase-8 or caspase-9activity directly (compare gray bars with white bars in
Figure 7B). When cells were preincubated with the
DEVD-CHO, no effect was seen on the TRAIL-induced
activation of caspase-8 in the absence of ABT-737, but
DEVD-CHO abrogated the ABT-737-induced increase
in TRAIL-induced caspase-8 activation (Figure 7B, top
panels). This is consistent with caspase-3/7 contributing
to the increase in caspase-8 activation seen in the pres-
ence of ABT-737. Caspase-9 activation by TRAIL alone or
by TRAIL plus ABT-737 was not affected by DEVD-CHO
(Figure 7B, middle panels). DEVD-CHO significantly
inhibited the TRAIL-induced activation of caspase-3 in
both the presence and the absence of ABT-737 (Figure 7B,
Garimella et al. Breast Cancer Research 2014, 16:R41 Page 16 of 21
http://breast-cancer-research.com/content/16/2/R41lower panels). These data are consistent with ABT-737
causing increased caspase-9 activation by caspase-8. This,
in turn, results in more caspase-3/7 activation and then
retrograde activation of caspase-8 by caspase-3/7.
Treatment of a panel of breast cancer cell lines with
5 μM ABT-737 (Figure 7C) by using sub-IC50 concentra-
tions of TRAIL, enhanced TRAIL-induced toxicity in all
of the breast cancer subtypes tested (TNBC/Basal B,
TNBC/Basal A, HER2 amplified, and ER + breast cancer)
(Figure 7C). The combined treatment of TRAIL plus ABT-
737 inhibited viability more than TRAIL alone (*P < 0.05)
or ABT-737 alone (**P ≤ 0.05) in all cells tested. The tox-
icity of the combined treatment was greater than the sum
of the toxicities for the individual treatments for all cell
lines (***P ≤ 0.05), except for MB157. Again the high sensi-
tivity to TRAIL alone in this cell line probably accounts for
the failure of ABT-737 to enhance significantly the toxicity
by this analysis.
Discussion
TRAIL is a promising cancer therapeutic agent showing
efficacy against tumor cells and not affecting normal
cells. However, in vitro experiments have found that
many cancer cell lines are resistant to TRAIL [5]. The
underlying determinants of TRAIL sensitivity are not
clearly understood. Investigations into the mechanisms in
cells that regulate sensitivity to TRAIL have implicated sev-
eral pathways and factors. Regulation of the TRAIL recep-
tors at the level of expression, localization to the cell
surface, and O-glycosylation of the receptor proteins par-
tially, but not fully, correlate with sensitivity (reviewed in
[5]). TRAIL-resistance is also associated with elevated ex-
pression of antiapoptotic factors like c-FLIP [36], IAP fam-
ily proteins [37], and BCL-2 [38].
In ongoing clinical trials, responses to TRAIL have been
rare, especially in solid tumors [21,22,32-35]. Therefore
we need to identify proteins that regulate the TRAIL path-
way, as they could potentially serve as predictive bio-
markers of TRAIL sensitivity and/or provide additional
targets for enhancing the efficacy of TRAIL.
To this end, we performed primary siRNA screens of
the human kinome, phosphatome, and some additional
genes to identify regulators of TRAIL-induced apoptosis
in the MB231 breast cancer cell line. We identified 150
genes (83 kinases or kinase-related genes, four phospha-
tases or phosphatase-related genes, and 63 other genes) as
putative negative regulators of TRAIL-induced caspase-3/7
activation. For this study, we adapted commercially available
assays of caspase-8, caspase-3/7, and cell viability for high-
throughput siRNA screens, including the identification of
highly sensitive biologically relevant controls. Good positive
correlation was found between those siRNAs that enhanced
TRAIL-induced caspase-3/7 and those that enhanced
TRAIL-induced caspase-8 activation (Figure 2Ci-ii).Good inverse correlation was seen between the TRAIL-
induced enhancement of caspase activation and the viabil-
ity of TRAIL-treated cells. Thus, the three assays together
strengthen the likelihood that the identified genes are
regulators of the TRAIL pathway. The identification of
several established negative regulators of apoptosis as
negative regulators of TRAIL-induced caspase-3/7 ac-
tivation, including BCL2L1 (BCL-XL), BCL2L2 (BCL-w),
BIRC2 (c-IAP1), and BIRC3 (c-IAP2), lends further sup-
port to the validity of the screen results.
Interestingly, other candidate genes identified by our
screens have been linked recently to TRAIL activity. For
example, the expression of argininosuccinate synthase 1
(ASS1) has been described as a member of a predictive
panel of 71 genes whose expression correlates with TRAIL
sensitivity [39]. ASS1 was the only gene in common be-
tween the 71-gene signature and the set of genes found in
our screen. Based on our experiments, ASS1 is a putative
negative regulator of TRAIL sensitivity, and LOF induced
an increase in caspase-3/7 activation (Figure 3). ASS1 is
the rate-limiting enzyme in arginine biosynthesis, and
interestingly, two studies demonstrated that loss of ASS1
sensitizes lymphoma and glioblastoma cells to apoptosis
induced by arginine deprivation [40,41]. The LOF of
ASS1, then, may result in arginine depletion and make
cells more susceptible to TRAIL-induced apoptosis.
Elucidating the mechanism by which ASS1 negatively
regulates TRAIL-induced apoptosis will require further
study.
Among the approximately 1,300 genes assessed at the
higher stringency (that of a 2-standard deviation change
in TRAIL-induced caspase-3/7 activity), these RNAi screens
did not identify positive regulators of TRAIL. Several poten-
tial positive TRAIL regulators were identified when the
stringency was relaxed to a 1-SD change in TRAIL-induced
caspase-3/7 activation (Additional file 3: Figure S1). None of
these putative positive regulators has been linked previously
to the regulation of TRAIL-induced apoptosis or apoptosis
in general, although one of the genes identified, PXK, has
been recently shown to enhance degradation of the activated
epidermal growth factor receptor (EGFR) [42]. We and
others have shown that EGFR activity can attenuate TRAIL-
induced apoptosis and that inhibition of the EGFR enhances
TRAIL-induced apoptosis [20,43,44]. Thus, PXK LOF may
enhance TRAIL activity by the downregulation of the EGFR,
although this hypothesis will require further study.
The absence of strong positive regulators in our RNAi
screens suggests that the primary regulation of TRAIL-
induced apoptosis is by inhibition of the TRAIL path-
way. However, our screen was focused on kinases and
phosphatases and included only 300 additional genes
from the druggable genome. Notably, caspase genes were
not among the screened targets, although, as shown by
the caspase-8 controls in our screen, these would have
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caspase activation and apoptosis. To identify positive regu-
lators of TRAIL-induced apoptosis, more-comprehensive,
genome-wide RNAi screens, using the assays developed for
this study, are quite likely to identify other positive regula-
tors (and negative regulators) of TRAIL.
A previous RNAi-based screen of 510 genes conducted
in HeLa cells identified both positive and negative regu-
lators of the TRAIL pathway [45]. The reported screen
included many kinases as candidate regulators of TRAIL,
but little overlap existed between our results and the re-
sults reported by Aza-Blanc and co-workers. Of the top
20 negative TRAIL-regulator genes identified in the previ-
ous study, only PIP5K1C was identified in our screens,
and none of the top 20 positive TRAIL-regulator genes
described in the previous report was among the positive
regulators our screen identified at relaxed stringency.
The differing results are likely the result of several sig-
nificant differences in our screens. First, we performed
the screen in a TNBC breast cancer cell line, whereas
the prior study was performed in the cervical carcinoma
HeLa cell line. It is likely that the predominant regula-
tors of TRAIL-induced apoptosis are different in different
cell types. Second, our primary selection of genes whose
LOF altered TRAIL activity was based on caspase-3/7 ac-
tivation 1 hour after the addition of TRAIL, whereas the
previous study measured viability 20 hours after the
addition of TRAIL. Thus, our screens were designed
principally to identify regulators that affect early steps
in TRAIL-induced apoptosis, contributing to the dif-
ference noted.
Review of the putative negative regulators identified in
our primary RNAi screens in MB231 revealed genes in-
volved in diverse cellular processes, including growth factor
receptor signaling (for example, BTK, ERBB-2, EPH6, ERK8,
FGFR2, FGFR4, JAK1, and SRC), cytoskeleton function (for
example,, ACTN4, KIF1A, LIMK2, MAGI1, and PKN1), bio-
energetics (for example, ACACB, ACLY, ATP5A1, CKB,
CKMT2, FN3K, HK1, HK2, IHPK3, PDK2, PFKL, and
PKLR), cell-cycle regulation (for example, CDK5R2,
CDKN2B, GAK, PIK3, PFTK1, and ZC3HC1), transcrip-
tional regulation (for example, HIPK1, HIPK2, NLK, and
PIM2), and DNA repair (for example, APEX1, PARP4, and
TLK). Also of note, several genes known to regulate
apoptosis negatively were identified (for example, AATK,
BCL2L1, BCL2L2, BIRC2, BIRC3, IKBKAP, IKBKB, PRKCI,
PIM2, and SPHK2).
The largest gene set in our RNAi library included the
known kinases and kinase-associated genes. Of the group
of kinases that were identified as hits, the majority of them
are serine/threonine kinases (33 of 83), whereas fewer
belonged to the tyrosine kinase (10 of 83), lipid kinase
(four of 83), or sugar/metabolism kinase (12 of 83) fam-
ilies. Interestingly, four kinases were identified (hexokinase1 (HK1), hexokinase 2 (HK2), pyruvate kinase liver and
red blood cells (PKLR), and phosphofructose kinase liver
(PKFL)), which regulate irreversible steps of the glycolysis
pathway (Figure 3). Several studies have previously found
that inhibition of glycolysis enhances TRAIL-induced cell
death [46-49].
Based on the gene-network analysis, four genes were
identified that appear at central nodes of an interaction
map generated by using the caspase-3/7 screening dataset,
PDPK1, IKBKB, SRC, and BCL2L1 (BCL-XL) (Figure 4A).
The caspase-8 and cell-viability screening data confirmed
these findings for BCL2L1 (BCL-XL) and PDPK1. PDPK1
phosphorylates and activates AKT. Constitutively active or
overexpression of AKT has been shown to confer TRAIL
resistance in several tumor types, including breast [18],
lung [50], gastric [51], and prostate [52]. Also, TRAIL can
activate SRC, leading to AKT activation and TRAIL re-
sistance [29]. Inhibition of the PI3 kinase/AKT path-
way has been found to enhance TRAIL-induced apoptosis
[43,50,51,53-57]. Therefore, identification of PDPK1 as
one of the key nodes provides a rationale for pursuing
studies on the combination of TRAIL with AKT inhib-
itors in treatment of TRAIL-resistant tumors.
NF-κB proteins are ubiquitously expressed proteins
that can protect cells from apoptosis. The inhibitors of
κB (IκB) family proteins regulate the activity of NF-κB.
IκB proteins block nuclear localization signals of func-
tional NF-κB dimers by binding to dimerization domains
and sequestering the dimers in the cytoplasm. IκB ki-
nases (IκBK) phosphorylate IκB on a serine residue, tar-
geting them for proteasomal degradation, thereby activating
NF-κB, which protects cells by increasing the expression of
antiapoptotic proteins [3,58,59]. Previously, we showed that
inhibition of NF-κB increases TRAIL sensitivity in breast
cancer cell lines [18]. Similar results were reported in other
cancer cell lines [18,60-63]. Again, our findings in this article
that IκBKB LOF leads to enhanced TRAIL-induced caspase
activation provide support for further studies of NF-κB in-
hibitors in combination with TRAIL.
Further to confirm our primary screen results, we per-
formed a secondary screen of 16 genes identified as
negative regulators of TRAIL-induced caspase activation
in four cell lines representing different subtypes of breast
cancer (TNBC, ER positive, and HER2 amplified) (Figure 5,
Table 1, and Additional file 8: Table S4). We selected
16 genes that were included in the network analysis in
Figure 4 and that both increased TRAIL-induced caspase-
3/7 activity and enhanced TRAIL-induced toxicity in a
viability assay. In MB231, 13 of 16 genes scored positive in
this assay (by using the criterion of 2-SD enhancement
in TRAIL-induced caspase-3/7 activation), and 15 of 16
genes scored positive at a lower-stringency cutoff (by using
the criterion of 1-SD enhancement in TRAIL-induced
caspase-3/7 activation). This high level of reproducibility
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ports the validity of the primary screen. All of the 16 genes
scored positive by using the high-stringency criterion in
MB468. The TNBC/basal A MB468 cell line is most
closely related to the TNBC/basal B MB231 cell line by
cDNA microarray expression analysis, and thus the high
degree of overlap between the two cell lines in this screen
is not surprising [26,64]. By contrast, fewer of the 16 genes
were scored positive in T47D (four at high stringency and
10 at low stringency) and SKBR3 (two at high stringency
and three at low stringency). The T47D cell line is an ER-
positive luminal breast cancer cell line, and the SKBR3 cell
line is an HER2-amplified luminal breast cancer cell line.
Thus they are more distantly related to the MB231 cell
line [26,64].
The only gene that scored positive in our screen at
high stringency in all four cell lines is alpha-actinin 4
(ACTN4). ACTN4 is a cytoskeletal protein that has been
found to interact with signaling molecules, chromatin-
remodeling factors, and transcription factors (reviewed
in [65]). Of note, ACTN4 can serve as a scaffold to pro-
mote AKT activation, and it has been shown to interact
with NF-κB in breast cancer cells (although the signifi-
cance of this latter interaction is not known) [65]. Thus,
it is plausible that by modulating activity through these
two antiapoptotic pathways, ACTN4 might serve as a
negative regulator of TRAIL-induced apoptosis. The mech-
anisms by which ACTN4 regulate TRAIL-induced apoptosis
in breast cancer cells will require further investigation. LOF
of BCL2L1 (BCL-XL) enhanced TRAIL-induced caspase-3/7
activation in three of the four cell lines at high stringency
and in all four cell lines when a lower stringency was used.
Expanded screening of five BCL2L1 siRNAs confirmed that
BCL2L1 LOF results in enhanced TRAIL activity in four
breast cancer cell lines (Figure 7A). A number of studies
have directly or indirectly implicated the BCL2 family
as regulators of TRAIL-induced apoptosis in breast
cancer cells [33,66-71].
In this study, we identified BCL2L1 (BCL-XL) as a key
node in determining sensitivity (Figure 4) and further
showed that inhibition of the BCL-2 family by the small-
molecule inhibitor, ABT-737, enhances TRAIL-induced
toxicity in breast cancer cell lines (Figure 7C). These re-
sults are in concordance with previous reports of the
combined use of TRAIL and ABT-737 in renal, lung,
prostate, and pancreatic cancer cell lines [72,73]. ABT-
737 is a BH3 mimetic inhibitor of BCL-XL, BCL-2, and
BCL-w [74]. Interestingly, both BCL-XL (BCL2L1) and
BCL-w (BCL2L2) were identified as negative regulators
of TRAIL-induced caspase-3/7 activation in the breast
cancer cells by our primary screen. This suggests that
the effects of ABT-737 may be due to inhibition of mul-
tiple BCL2 family members. Most important, the con-
comitant treatment with ABT-737 and TRAIL resultedin significantly more cell death in both sensitive and resist-
ant breast cancer cell lines of all phenotypes (Figure 7C).
This suggests that the BCL2 family may play a role more
broadly in regulating TRAIL sensitivity in breast cancer
cells and is worth further investigation.
SRC enhanced TRAIL-induced caspase-3/7 activation
in the two TNBC cell lines at high stringency (MB231
and MB468) and in the T47D cell line at lower strin-
gency. SRC is an important kinase regulating cell-survival
pathways [75]. In our study, inhibition of SRC resulted in
a decrease in the activity of the PI3K/AKT/mTOR path-
way, consistent with published findings that SRC regulates
the activity of the PI3K/AKT/mTOR and that inhibition
of this pathway increases TRAIL sensitivity (Figure 6B)
[28,29,76-79]. In the present study we showed that SRC is
a key node of TRAIL-induced apoptosis, as illustrated in
the pathway-analysis map (Figure 4A), and that inhibition
of SRC by PP2 increases the sensitivity of breast cancer
cells to TRAIL (Figure 6) [28,29]. The most significant ef-
fects of SRC inhibition on TRAIL-induced cell death were
observed in the TNBC cells (both basal A and basal B).
The TNBC/basal A breast cancer cell lines are relatively
resistant to TRAIL compared with the TNBC/basal B cell
lines [20]. Our data raise the possibility that combinations
of TRAIL and SRC inhibitors may be of use in TNBC.
The effects of TRAIL plus PP2 in the HER2-amplified and
ER-positive cells were less dramatic. Although the reason
for this is not clear, the focus of further studies with SRC
inhibitors combined with TRAIL should be in TNBC cells.
Conclusions
In this study, we successfully applied complementary siRNA
screens by using different end-point assays to identify nega-
tive regulators of TRAIL-induced apoptosis in breast cancer
cells. The identification of PDPK1, IKBKB, SRC, and BCL2L1
as central nodes connecting the genes identified is consistent
with previous studies. Importantly, this study demonstrates
that phenocopying SRC and BCL2L1 LOF by pharmacologic
inhibition can sensitize TRAIL-resistant breast cancer cell
lines to TRAIL-induced apoptosis. In these screens, we iden-
tified a large number of additional genes as potential regula-
tors of TRAIL-induced apoptosis, whose role in the TRAIL
pathway is heretofore unknown. It will require further study
to elucidate how they regulate the TRAIL pathway. The
genes identified by this screen are likely to include novel
therapeutic targets that can be tested in combination with
TRAIL in treating a variety of tumors, including breast
cancer.
Additional files
Additional file 1: Table S1. Caspase-8, caspase-3/7, and cell viability
siRNA primary screening data in MB-231 cells in the absence and
presence of TRAIL. Data are for four different siRNAs per gene (A, B, C,
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absence of TRAIL.
Additional file 2: Table S2. Genes and siRNA sequences selected for
secondary screening of putative regulators of TRAIL-induced apoptosis.
Additional file 3: Figure S1. Caspase-3/7 and cell-viability RNAi screens
of the phosphatome and TRAIL-induced apoptosis in MB231 cells. (A)
Controls included in the RNAi screens of the phosphatome gene set in
MB231 cells for (i) caspase-3/7 activation and (ii) cell viability in the
absence (white bars) or presence (black bars) of TRAIL. Cells were
siRNA-transfected, treated with TRAIL, and assessed for caspase-3/7
activation and cell viability, as described in Figure 2. Data are normalized
to the mean value of siNeg-transfected cells in the absence of TRAIL and
are shown as the mean and standard deviation for each group. Comparison
of TRAIL treated with siNeg-transfected untreated cells demonstrated a
significant increase in caspase-3/7 activation and a significant decrease
in viability. siCASP8 reduced caspase-3/7 activation (P = 1.0 × 10-14) and
increased viability (P = 1.5 × 10-14) compared with siNeg-transfected
cells. siFLIP increased caspase-3/7 (P = 1 × 10-8) activation and decreased
viability (P = 7.0 × 10-7) compared with siNeg-transfected cells. ***P < 0.001.
(B) To assess further the sensitivity of our assays, we confirmed that silencing
Polo-like kinase 1 (PLK1), an essential protein in many cell lines, activated
caspase-8, caspase-3/7, and decreased cell viability. The dashed line indicates
the 1-SD value for each assay; the red dots indicate those siRNAs inducing
fold-changes greater than 1 SD. (C) Identification of putative positive
regulators of TRAIL-induced apoptosis. Genes for which three or four
siRNAs decreased activation of caspase-3/7 in the presence of TRAIL 1
or more SDs over that observed in siNeg-transfected cells plus TRAIL
were considered as putative positive regulators of TRAIL-induced
apoptosis. The dashed line indicates the 1-SD fold-change, and a vertical
line joins those siRNAs that induced at least this level of change for each
gene. Data for the control siRNAs, siNeg, siCASP8, and siFLIP are included for
reference.
Additional file 4: Table S3. Primary screen Z-factors calculated for the
viability, caspase-3/7, and caspase-8 assay plates.
Additional file 5: Figure S2. Interaction network analysis of putative
negative regulators of TRAIL-induced apoptosis. An interaction network
generated by analysis of the 150 genes for which three or more siRNAs
induced increased TRAIL-induced activation of caspase-3/7 levels. All
symbols are presented as depicted by the Ingenuity Pathway Analysis
software. Gene names in black and linked by solid lines indicate evidence
for a mechanistic relation between the proteins indicated. Gene names in
blue and linked by dashed lines indicate correlative relations between the
proteins indicated, but no mechanistic relation has been established.
Additional file 6: Figure S3. Validation of genes identified by
interaction analysis. Caspase-8 and caspase-3/7 activation, and cell viability
in the absence (empty bars) and presence (black bars) of TRAIL for four
siRNAs (A-D) corresponding to the genes shown. Mean data (±1 standard
deviation) for control siRNA (siNeg) transfected cells are shown in each
graph. The dashed line indicates the relevant 1 SD value for each assay, and
the red dots indicate those siRNAs inducing fold-changes greater than 1 SD.
Additional file 7: Figure S4. Caspase-3/7 activation by TRAIL in breast
cancer cell lines. Cell lines were treated with increasing concentrations of
TRAIL, as indicated along the X axis for 1 hour, and caspase-3/7 activation
was measured by Caspase-Glo-3/7 assay, as described earlier.
Additional file 8: Table S4. Caspase-3/7 siRNA secondary screen in a
panel of breast cancer cell lines in the absence and presence of TRAIL.
Data are for four different siRNAs per gene, shown as fold-change relative
to siNeg-transfected cells in the absence of TRAIL. Values indicated in red
are >2 SDs higher than TRAIL-induced caspase-3/7 in siNeg-treated cells.
Values indicated in blue are >1 SD higher than TRAIL-induced
caspase-3/7 in control siRNA (siNeg)-treated cells.
Additional file 9: Figure S5. BCL-XL protein expression in the breast
cancer cells. (A) Expression of BCL-XL was measured by immunoblotting in
the four cell lines used in the secondary RNAi screen. (B) Two BCL-XL-specific
siRNAs (siBCL2L1.3 and siBCL2L1.5) were compared with a negative control
siRNA (siNEG) for their ability to enhance TRAIL-induced caspase-3/7 activity,
as described earlier and in parallel for their knockdown of BCL-XL protein. (C)
Levels of BCL-XL protein were measured by immunoblotting in cells treatedwith ABT-737 (5 μM) for the times indicated. In all of the blots, HSC70 is
shown as a loading control, and MW in kilodaltons is shown to the left of
the panels.
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